argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$925.70−16.34 (-1.73%)
Close on Nov 20, 2026Market cap –P/E 47.3Yield –
argenx net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was $1.29B, up 55.1% from the year before. The highest annual figure on record is $1.29B in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | +55.1% |
| FY2024 | Dec 31, 2024 | $833.04M | – |
| FY2023 | Dec 31, 2023 | -$295.05M | – |
| FY2022 | Dec 31, 2022 | -$709.59M | – |
| FY2021 | Dec 31, 2021 | -$408.27M | – |
| FY2020 | Dec 31, 2020 | -$608.46M | – |
See a number that looks wrong?